For these high-risk lesions, the use of tamoxifen (selective estrogen receptor modulator [SERM]) reduces the risk of invasive carcinoma by 49% (p < 0.00001) and of carcinoma in situ by 50% (p < 0.002). The gene discussed is ESR1; the disease is in situ carcinoma.